Player is loading...

Embed

Embed code

Transcriptions

Note: this content has been automatically generated.
00:00:00
first of all I'd like to thank the
00:00:01
organizers for giving me the opportunity
00:00:03
to talk about our appeal switzerland and
00:00:06
so as you all know RP is a severe
00:00:16
complication of period at preterm birth
00:00:18
commuters on the screen here let's move
00:00:23
over here is a severe complication of
00:00:26
preterm birth but the incidents of ROP
00:00:28
or an RP treatment switzerland is
00:00:30
largely unknown and furthermore we know
00:00:33
that the ROP screening criteria differ
00:00:35
between countries and also between
00:00:37
different between centers in Switzerland
00:00:39
so the aims of our study was first to
00:00:43
analyze ROP treatment and are pretreated
00:00:45
incidents in Switzerland and the second
00:00:47
a monster sets of screening criteria can
00:00:49
be optimized methods were that we use
00:00:54
MDS data manipulated the data set data
00:00:56
meaning all patients born in Switzerland
00:00:59
with low 32 weeks after stations age and
00:01:02
we use data on patients bond within 2016
00:01:05
2015 for the second aim to analyze
00:01:10
screening criteria we developed a new
00:01:12
model and we used logistic regression
00:01:15
analysis of 50 computer databases for
00:01:18
all children born between 2006 in 2012
00:01:23
then we developed a model including
00:01:25
several risk factors for ROP and will be
00:01:30
stepwise eliminated a the risk factors
00:01:34
for lower predictive value and we came
00:01:37
up with seven known risk factors little
00:01:38
included in the model and we applied the
00:01:42
bottle on patients bond between
00:01:43
2013-2015 to see if we can really
00:01:48
predict the patients who develop RP
00:01:50
treat or needed treatment later on in
00:01:57
our database between 2006 in 2015 with
00:02:01
7870 in preterm infants below to 32
00:02:05
weeks of gestational age
00:02:07
the first problem we had was that we had
00:02:10
more than 1,000 patients who did not
00:02:12
have
00:02:13
data recorded on RP so we tried to track
00:02:16
down the patients and to complete the
00:02:18
datasets and we are able to complete
00:02:21
1942 of these datasets and so we came up
00:02:24
with only 2.2% of missing data which was
00:02:27
quite satisfactory I think that's what a
00:02:29
lot of work took us more than a year to
00:02:31
track down all these patients but i
00:02:32
think it was worth it and coming to our
00:02:36
results on the right hand side just
00:02:38
we'll start with this one is Rp
00:02:40
incidence in England published 2014 and
00:02:45
we see that the ROP treatment incidents
00:02:48
is increasing after 2005 and is also
00:02:52
published other studies but if you look
00:02:55
on the left side this is our data we see
00:02:56
between 2006 in 2015
00:02:59
there is no in no increase of ROP
00:03:01
treatment we have ROP treatment in the
00:03:03
study population between 0.8 percent in
00:03:07
2015 and 2.0 percent in 2010 looking a
00:03:14
little more closely at data stratified
00:03:17
by educational age we see of course that
00:03:20
patients with lower gestational age 24
00:03:22
weeks at RP intervention 14.5 percent 25
00:03:26
weeks of gestation at 7.3 percent and
00:03:29
the other ones at a lower incidence of
00:03:32
ROP treatment
00:03:33
overall the RP treatment was 12.2
00:03:36
percent of this patient group which is
00:03:40
much much lower than published in other
00:03:41
countries for example in Germany there's
00:03:44
a studies showing three-point-nine
00:03:46
percent treatment in these patients if
00:03:50
we look at these patients 29 30 31 weeks
00:03:54
this is more than half of the population
00:03:55
group and we see the incidence of ROP
00:03:59
treatment is between 0.1 0.2 percent so
00:04:04
this means we're screening this paper
00:04:06
population more than 99 of the percent
00:04:10
of the patients are necessarily because
00:04:12
there's no further treatment and we
00:04:14
apply pain and stress for the patients
00:04:15
and we don't have a consequence
00:04:17
so the question is can we define these
00:04:21
patients or identify these patients more
00:04:23
precisely and we don't have to screen
00:04:26
all of them
00:04:27
like I said before we developed this
00:04:31
model of patients on between 2006 in
00:04:34
2012 and we have respectively applied
00:04:38
these model we received on patients bond
00:04:40
between 2013-2015 between 2013-2015 with
00:04:45
a little more than 2,000 preterm infants
00:04:48
in the database in nineteen of them so
00:04:50
less than 1% were treated for ROP if we
00:04:56
look at these data we see of these 19
00:04:59
patients if we want to have 19 true
00:05:03
positives the sensitivity of one person
00:05:05
one hundred percent or 1.0 we need to
00:05:08
test all of them
00:05:10
this is quite disappointing that we did
00:05:12
not come up with the clear model this is
00:05:15
easier to identify these patients
00:05:17
however if we have one false negative
00:05:21
and 18 true positives sensitivity of
00:05:25
94.7 percent we only have to screen here
00:05:30
sorry we only have to screen 281
00:05:33
patients meaning only thirteen percent
00:05:36
of the patients needed to be screened to
00:05:39
have a sensitivity of 94.7 point further
00:05:43
malformed or this one patient we missed
00:05:45
had a congenital never stoma so probably
00:05:48
different physiology with high levels of
00:05:50
growth factor sensible in the blood and
00:05:52
probably higher risk factor for
00:05:54
developing RP so this is the result of
00:05:58
our body to the moment I think we can
00:06:03
continue to develop a more precise model
00:06:06
and test the model prospectively this
00:06:09
would be the same for the next year's so
00:06:12
I'd like to conclude that the rate of
00:06:14
ROP treatment does not increase increase
00:06:16
over time the rate of ROP treatment
00:06:19
switzerland is low its one-point-two
00:06:21
percent for all patients below 32 weeks
00:06:23
after station h is 0.1 percent of
00:06:26
patients between 29 and 31 weeks and it
00:06:30
might be as possible to optimize
00:06:32
existing ship screening criteria and
00:06:34
exact model on screening criteria should
00:06:36
be developed and tested prospectively so
00:06:39
thank you very much and
00:06:40
happy to take questions

Share this talk: 


Conference program

Welcome Words
M. Roth-Kleiner, R. Arlettaz Mieth
10 Jan. 2017 · 9:33 a.m.
526 views
Short Reports Introduction
E. Giannoni, T. Karen, Resp. Lausanne, Zürich
10 Jan. 2017 · 9:38 a.m.
Association of Axonal Injury and Preeclampsia
Katrina Evers, Neonatology UKBB
10 Jan. 2017 · 9:39 a.m.
182 views
Q&A - Association of Axonal Injury and Preeclampsia
Katrina Evers, Neonatology UKBB
10 Jan. 2017 · 9:44 a.m.
102 views
Retinopathy of Prematurity
Roland Gerull, Bern
10 Jan. 2017 · 9:47 a.m.
154 views
Q&A - Retinopathy of Prematurity
Roland Gerull, Bern
10 Jan. 2017 · 9:54 a.m.
Parechovirus Infection: A Rare Cause of Neonatal Encephalitis (in French)
Dr Truant AS, Cheffe de clinique, Néonatologie, CHUV, Lausanne
10 Jan. 2017 · 9:59 a.m.
350 views
Q&A - Parechovirus Infection: A Rare Cause of Neonatal Encephalitis
Dr Truant AS, Cheffe de clinique, Néonatologie, CHUV, Lausanne
10 Jan. 2017 · 10:04 a.m.
234 views
112 views
Genetic Susceptibility to Neonatal Group B Streptococcal Disease
Alessandro Borghesi, Fellay lab, EPFL
10 Jan. 2017 · 10:17 a.m.
131 views
Q&A - Genetic Susceptibility to Neonatal Group B Streptococcal Disease
Alessandro Borghesi, Fellay lab, EPFL
10 Jan. 2017 · 10:25 a.m.
Psychomotor Development in Children Prenatally Exposed to Methadone
G. Grand-Guillaume-Perrenoud, Pediatrics, Children's University Hospital Geneva
10 Jan. 2017 · 10:27 a.m.
Q&A - Psychomotor Development in Children Prenatally Exposed to Methadone
G. Grand-Guillaume-Perrenoud, Pediatrics, Children's University Hospital Geneva
10 Jan. 2017 · 10:34 a.m.
Introduction to Christoph Berger's Presentation
C. Kind, R. Gerull, Resp. St.Gallen, Bern
10 Jan. 2017 · 10:37 a.m.
Vertical Infections: An Update
Christoph Berger, Zürich
10 Jan. 2017 · 10:40 a.m.
253 views
Q&A - Vertical Infections: An Update
Christoph Berger, Zürich
10 Jan. 2017 · 11:15 a.m.
Introduction to Eric Giannoni's Presentation
R. Pfister, S. Kämpfen, Resp. Geneva, Basel
10 Jan. 2017 · 11:44 a.m.
Sepsis, Antibiotics and Resistances: Where Are We?
Christoph Bührer, Berlin
10 Jan. 2017 · 2:21 p.m.
145 views
Use and Abuse of Antibiotics in Neonatology
Martin Stocker, Lucerne
10 Jan. 2017 · 2:50 p.m.
291 views
Panel Discussion : Controversies on Use of Antibiotics in Neonatology
Martin Stocker, Christoph Berger, Eric Giannoni, Christoph Bührer
10 Jan. 2017 · 3:10 p.m.
105 views
Introduction to Christoph Bührer's Presentation
Romaine Arlettaz Mieth , Neonatologist, Zürich, President of the Organizing Committee
10 Jan. 2017 · 3:47 p.m.
Evidence-Based Haemodynamic Management in Neonatal Sepsis
Christoph Bührer, Berlin
10 Jan. 2017 · 3:48 p.m.
416 views
Q&A - Evidence-Based Haemodynamic Management in Neonatal Sepsis
Christoph Bührer, Berlin
10 Jan. 2017 · 4:16 p.m.
SwissNeoDose Project
Marc Pfister, Ped Pharmacology, UKBB
10 Jan. 2017 · 4:20 p.m.
112 views
Awards (Case of the Year; Milupa; Best Poster Case Report; Best Oral Short Presentation) & Closing Comments
Matthias Roth-Kleiner, CHUV, President of the SSN
10 Jan. 2017 · 4:30 p.m.